All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells

PURPOSE: Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro. The IDH2 inhibitor enasidenib (AG-221) has been approved by the FDA as a first-in-class inhibitor for the treatment of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yundeok, Jeung, Hoi-Kyung, Cheong, June-Won, Song, Jaewoo, Bae, Soo Han, Lee, Jong In, Min, Yoo Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471081/
https://www.ncbi.nlm.nih.gov/pubmed/32882760
http://dx.doi.org/10.3349/ymj.2020.61.9.762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471081/
https://www.ncbi.nlm.nih.gov/pubmed/32882760
http://dx.doi.org/10.3349/ymj.2020.61.9.762

Ejemplares similares